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4 
Abstract 56 
One reason for increased pertussis incidence is the adaptation of Bordetella pertussis to 57 
vaccine-induced immunity by modulating its genomic structure. This study, EUpert IV, 58 
includes 265 isolates collected from nine European countries during 2012 to 2015 (n=265) 59 
and compares the results to previous EUpert I-III studies (1998-2009). The analyses included 60 
genotyping, serotyping and pulsed-field gel electrophoresis (PFGE) and multi-locus variable-61 
number tandem repeat analysis (MLVA). Genotyping results showed only small variation 62 
among the common virulence genes of B. pertussis. Frequencies of serotypes Fim2 and Fim3 63 
varied among the four collections. Genomic analyses showed that MLVA type 27 increased 64 
to 80% between the periods of 1998-2001 and 2012-2015. Two PFGE profiles, BpSR3 65 
(29.4%) and BpSR10 (27.2%), constituted more than 50% of the circulating isolates in the 66 
present collection. Our study indicates that the European B. pertussis population is changing 67 
more homogenous after the introduction of acellular pertussis vaccines. 68 
 69 
 70 
 71 
 72 
 73 
 74 
 75 
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5 
Introduction of whole-cell pertussis vaccines (WCVs) dropped the number of reported 76 
pertussis cases significantly during the 1950s. Since the mid-1990s WCVs have been 77 
gradually replaced by acellular pertussis vaccines (ACVs) in many European countries. 78 
Although vaccines and vaccination schedules vary, vaccination coverage is high (>90%) (1, 79 
http://vaccine-schedule.ecdc.europa.eu/pages/scheduler.aspx. Accessed 04/04, 2017). 80 
However, pertussis remains endemic, and many outbreaks have occurred during the past ten 81 
years including Australia, the UK and the USA (2-4). One explanation is adaptation of 82 
Bordetella pertussis to vaccine induced immunity. Therefore, monitoring of B. pertussis 83 
populations is essential for evaluating the impact of bacterial changes on vaccine efficacy.   84 
 To investigate changes in B. pertussis populations in Europe with different 85 
vaccination history, vaccines and schedules and to evaluate the effect of switch from whole 86 
cell pertussis vaccine (WCV) to acellular vaccines (ACV), “European Research Programme 87 
for Improved Pertussis Strain Characterization and Surveillance” (EUpertstrain) was 88 
established (5). So far, three panels of B. pertussis isolates (named as EUpert I-III) have been 89 
collected. EUpert I (1998-2001) included 102 strains from five countries, EUpert II (2004-90 
2005) included 154 strains from eight countries and EUpert III (2007-2009) included 140 91 
strains from seven countries. Results from these studies have been published earlier, 92 
including multi-locus antigen sequence typing (MAST), fimbrial serotyping, pulsed-field gel 93 
electrophoresis (PFGE) profiling and multi-locus variable-number tandem repeat analysis 94 
(MLVA) (6, 7). Results showed that specific allelic types of the genes coding for pertactin 95 
(prn) prn2, pertussis toxin (ptxA) ptxA1 and the pertussis toxin promoter (ptxP) ptxP3, and of 96 
the fimbrial antigen (Fim) Fim3 were dominant. For fim3 genotyping, both fim3-1 and fim3-2 97 
have been common in all studies. In addition, dominant PFGE profiles BpSR3, BpSR5 and 98 
BpSR10 increased (BpSR3: from 0% to 22%; BpSR5 from 6% to 10% and BpSR10 from 99 
10% to 20%) in EUpert III collection, whereas BpSR11, the most prevalent profile in EUpert 100 
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6 
I and II collections started to decrease (from 26% to 13%). With MLVA types (MT), MT27 101 
has been dominant throughout all studies.  102 
 In this study, a fourth panel (EUpert IV) of 265 B. pertussis clinical isolates was 103 
collected from nine European countries during 2012-2015. All study countries are using 104 
ACVs (Table 1). Finland, France, The Netherlands and Sweden also participated in all of the 105 
previous three studies. The selection criteria of clinical isolates have remained unchanged for 106 
all collections. The typing methods used were as described above. This study provides a 107 
unique opportunity to systemically evaluate the changes in the B. pertussis bacterial 108 
populations over the last 15 years in European countries with different vaccination strategies.  109 
  110 
MATERIAL AND METHODS 111 
 112 
Isolates 113 
265 B. pertussis isolates were collected during 2012-2015. Most of the isolates were collected 114 
during 2013-2014 (N = 236). Isolates were collected from nine European countries and the 115 
target number of isolates for each country to submit was set at n=30. However, in Denmark, 116 
Finland and Italy the total number of isolates was less than 30 during 2013-2014. The 117 
following number of isolates were received: Belgium (N = 38), Denmark (N = 27), Finland 118 
(N = 28), France (N = 29), Italy (N = 20), The Netherlands (N = 32), Norway (N = 32), 119 
Sweden (N = 29) and the United Kingdom (N = 30). For Italy, all isolates were collected 120 
from the Rome area as no other isolates were available.  121 
 122 
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Selection criteria and collection of patient data 123 
The selection criteria for EUpert IV study were the same as those used in the previous EUpert 124 
I-III studies: 125 
1. B. pertussis isolates should be selected from different geographical regions and be 126 
epidemiologically unrelated 127 
2. An equal number of isolates from vaccinated (N=15) and unvaccinated individuals 128 
(N=15) should be collected. Selection of isolates should be made from individuals 129 
younger than 5 years of age where possible.  130 
3. For those countries with large numbers of isolates in their collections, isolates should 131 
be randomly selected in addition to the above criteria.  132 
 133 
Data collection included original code of isolate, country, date of collection, city and 134 
characteristics of patients from whom B. pertussis was isolated. The patient characteristics 135 
included gender, age, vaccination status, number of doses received and hospitalization status 136 
(7). 137 
 138 
Culture 139 
Isolates were first cultured in local laboratories and were then shipped in frozen storage tubes 140 
to University of Turku, Finland. All isolates were cultured on Regan-Lowe medium (without 141 
cephalexin) at + 35°C for 48h.  142 
 143 
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8 
MAST 144 
Polymorphisms in the genes encoding proteins included in the current ACVs (ptxA, prn and 145 
fim3) and the pertussis toxin promoter (ptxP) were analyzed as described previously (8-11). 146 
Bacterial suspension in deionized H2O (Ultrapure) was used as a template. In brief, bacterial 147 
growth harvested (10 μl loop) from culture plate was suspended in 300µl of deionized H2O 148 
(Ultrapure), vortexed and then heated at + 95°C for 30 minutes. This template was used in the 149 
polymerase chain reaction (PCR) assays. Reference strains with known alleles were included 150 
as positive controls in each run of each assay. Different alleles of genes mentioned above 151 
were determined with size comparison or by sequencing the specific targets in the gene. 152 
 153 
Serotyping  154 
Fimbrial serotyping (Fim2 or Fim3) was done with specific ELISA as described previously 155 
(11). Shortly, specific monoclonal antibodies against Fim2 or Fim3 were used to detect the 156 
serotype of each isolate. Reference strains S1 (Fim2) and S3 (Fim3) and monoclonal 157 
antibodies [06/124 (Fim2) and 06/128 (Fim3)] (mAbs) were obtained from the National 158 
Institute for Biological Standards and Control (NIBSC), Potter´s Bar, England (12).  159 
 160 
MLVA 161 
For MLVA, the variable number of tandem repeats in six loci (VNTR1, VNTR3a, VNTR3b, 162 
VNTR4, VNTR5 and VNTR6) was defined as described previously and named according to 163 
MLVA profiles described by Schouls et al (13, 14). Results were expressed as MLVA type 164 
(MT) e.g. MT18, MT27 etc. Reference strains with known MT were included as positive 165 
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9 
controls in each run. New MTs were submitted for MLVA database 166 
(http://www.mlva.net/bpertussis/default.asp) administrator for nomenclature. 167 
 168 
PFGE 169 
All isolates were analyzed according to the standardized recommendations for typing of B. 170 
pertussis with minor modifications using XbaI (#R0145S, New England Biolabs, the USA) as 171 
a restriction enzyme (7, 15, 16). PFGE profiles were defined as individual profiles with 172 
distinct DNA band patterns (at least one band difference) and were designated as BpSR1, 173 
BpSR2, BpSR3, etc. (17, 18). Isolates with new profiles were designated as EU4_1, EU4_2 174 
etc. according to the study name. A cluster analysis was performed with the unweighted-pair 175 
group method with arithmetric mean (UPGMA) with 1% band tolerance and 1% optimization 176 
settings. The same band tolerance and optimization settings were used in the previous EUpert 177 
I-III studies (7). For cluster group analysis, UPGMA with 2% band tolerance and 1.5% 178 
optimization settings was used as in the previous EUpertstrain studies. Strains 18323 (PFGE 179 
cluster I), Tohama I (PFGE cluster II), Bp134 (PFGE cluster III), B902 (PFGE cluster IVα), 180 
FIN6 (PFGE cluster IVβ), FIN12 (PFGE cluster IVg), FR287 (PFGE cluster V) and FINR21 181 
(PFGE cluster VII) were included in the dendrogram as reference strains (7, 16). 182 
 183 
Pertactin (PRN) deficiency 184 
Pertactin deficiency was measured by specific ELISA as described earlier (19). In short, 185 
whole bacterial lysate was used as a coating antigen. Production of PRN was detected with 186 
specific mAbs, kindly provided by the National Institute for Public Health and the 187 
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10 
Environment (RIVM), The Netherlands. French strain FR3693 (negative for PRN) and 188 
purified PRN were used as controls. 189 
 190 
Vaccination status 191 
During the period 2012-2015, 130 (49.1%) of the infected individuals were vaccinated and 192 
135 (50.9%) were unvaccinated. 193 
 194 
Statistical analysis 195 
BioNumerics software version 6.6 (Applied Maths, Sint-Martens-Latem, Belgium) was used 196 
to calculate PFGE cluster analysis. Chi-square tests for p-values between vaccinated and 197 
unvaccinated subjects were calculated using GraphPad prism 4.0 version (San Diego, CA, 198 
USA). Two tailed P values < 0.05 were considered significant. The Simpson diversity index 199 
(SDI) was calculated based on the formula D = 1- Ʃn(n-1)/N(N-1) where n indicates number 200 
of individual profiles and N number of all profiles. 201 
 202 
RESULTS 203 
 204 
A summary of EUpert IV study results and isolate characteristics are presented in Table 2. 205 
Below, these results are described and compared to previous EUpert I-III studies. 206 
 207 
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11 
ptxA alleles 208 
Strains used for production of ACVs contain ptxA2 and ptxA4 alleles as described previously 209 
(20). In this study, all 265 isolates harbored the ptxA1 allele (Table 2). All isolates included in 210 
EUpert I-III studies also harbored the ptxA1 allele (6). 211 
 212 
ptxP alleles 213 
In this study, 253 isolates (95.5%) carried the ptxP3 allele and 12 (4.5%) carried the ptxP1 214 
allele. In the EUpert I study 1998-2001, the frequency of ptxP1 and ptxP3 allele were similar 215 
(39% vs. 50%). Since then ptxP3 has become clearly dominant and from the EUpert III study 216 
onwards the frequency has been > 95% (6).  217 
 218 
prn alleles                           219 
Strains used for production of ACVs contain prn1 or prn7 (20). In this study, four prn alleles 220 
were detected: prn1, prn2, prn3 and prn9. For two isolates the allele could not be defined, 221 
because of partial or complete deletion of the prn gene. The most common allele was prn2 222 
with 255 (96.2%) isolates. Prn1 and prn9 were both found with three isolates (1.1%) and 223 
prn3 with two isolates (0.8%). The prn2 allele has been dominant (>75% of tested isolates for 224 
prn) in the previous EUpert I-III studies (6). 225 
 226 
Fim serotype and fim3 alleles 227 
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12 
The Fim3 serotype predominated (>67%) in earlier EUpert I-III studies (6). In the current 228 
EUpert IV study, 141 (53.2%) isolates were Fim3, 120 (45.3%) Fim2, three (1.1%) were 229 
Fim2,3 and one (0.4%) isolate was deficient for Fim2 and Fim3 (Figure 1). In Denmark 230 
(22/27, 81.5%) and Finland (22/28, 78.6%) Fim2 was dominant, whereas in France (27/29, 231 
93.1%), Sweden (24/29, 82.8%) and the UK (19/30, 63.3%) Fim3 was prevalent. In other 232 
study countries distribution between the two serotypes was close to equal. We also compared 233 
serotype with vaccination status of the subject. No correlation between serotypes and 234 
vaccination status was found (p = 0.709). 235 
 For fim3 alleles, 190 (71.7%) isolates carried fim3-1, 72 (27.2%) carried fim3-2, two 236 
(0.8%) carried fim3-4 and one (0.4%) fim3-3. In France, Sweden and the UK, the distribution 237 
between fim3-1 and fim3-2 were equivalent, whereas in other countries fim3-1 was dominant.  238 
 239 
MLVA 240 
MT27 was dominant in the EUpert I and III studies (MLVA not performed in EUpert II). In 241 
the EUpert IV, 20 MTs (20/265, 7.5%) were identified. In the EUpert I study 18 MTs 242 
(17.6%) out of 102 isolates and in EUpert III 15 MTs (10.7%) among the 140 isolates were 243 
identified (Table 3). In the current study, 214 (80.8%) isolates harbored MT27. The second 244 
most common type with 18 isolates (6.8%) was MT28 and third most common with seven 245 
(2.6%) isolates was MT18. In addition, 15 other MTs (12, 25, 29, 32, 33, 36, 38, 55, 60, 77, 246 
95, 114, 158, 312 and 324) were found among 26 (9.8%) isolates, and two new MTs were 247 
detected (MT335 and MT336). In all countries, except Denmark, MT27 was dominant. In 248 
Denmark, 48.2% carried MT27, whereas other types such as MT28 (29.6%) constituted more 249 
than half of the circulating isolates. However, MT27 and MT28 are close to each other as 250 
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13 
there is only one difference in number of repeats of variable number of tandem repeat 251 
(VNTR) 6. MT18 however, has seven repeats in VNTR3-2, whereas MT27 has none. 252 
Otherwise the structures are identical.  253 
 254 
PFGE profiles and association to Fim serotype and genotype 255 
42 PFGE profiles were identified among EUpert IV study. The number of different profiles 256 
identified in earlier studies is as follows: EUpert I, 33 of 102 (32.4%), in EUpert II, 36 of 154 257 
(23.4%) and in EUpert III, 29 of 140 (20.7%) isolates (Table 3). Throughout the studies, five 258 
most common PFGE profiles have been BpSR3, BpSR5, BpSR10, BpSR11 and BpSR12. In 259 
the previous EUpert I and II studies BpSR11 was the dominant profile and the number of 260 
isolates with profiles other than the five most common profiles was high (Figure 2). 261 
However, in the EUpert III study, the frequencies of BpSR3 and BpSR10 started to increase, 262 
whereas frequencies of BpSR11 and other profiles decreased. In the current study, the 263 
frequency of BpSR3 (78/265, 29.4%) and BpSR10 (72/265, 27.2%) further increased and 264 
number of isolates with BpSR11 (39/265, 14.7%) and other (19.6%) profiles decreased or 265 
remained the same as previously reported (6, 7). The most common profile BpSR3 belongs to 266 
the cluster IV, BpSR10 to the cluster IVα, BpSR11 to the cluster IVβ, BpSR5 to the cluster 267 
IV and BpSR12 to the cluster IVg. From the other PFGE profiles, 21 new profiles were 268 
detected (Figure 4). These new profiles belonged mainly to cluster VII, but were also found 269 
from clusters IV, IVα, IVβ, IVg and III. When we analyzed country-based data, BpSR3 was 270 
dominant in Denmark (18/27, 66.7%), Finland (16/28, 57.1%) and Norway (14/32, 43.8%). 271 
However, no BpSR3 profile was found from Sweden. BpSR10 was dominant in The 272 
Netherlands (14/32, 43.8%) and Sweden (11/29, 37.9%). In Belgium, the frequencies of both 273 
BpSR3 (12/38, 31.6%) and BpSR10 (14/38, 36.8%) were high. Figure 3 shows distribution of 274 
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14 
main PFGE profiles by country and Figure 4 shows all 42 PFGE-profiles identified in the 275 
EUpert IV study. 276 
 When we compared the two most common PFGE profiles BpSR3 and BpSR10 found 277 
in the EUpert IV study with Fim2 and Fim3 serotypes, we observed that most of the isolates 278 
with BpSR3 profiles were Fim2 (66/78, 84.6%) serotype, whereas BpSR10 represented both 279 
Fim3 (37/64, 57.8%)  and Fim2 (25/64, 39.1%). In previous EUpert I-III studies, however, 280 
isolates belonging to profile BpSR3 were associated with Fim3 serotype (Range: 74.2-100% 281 
of the isolates), whereas BpSR10 was linked to Fim3 (96.6-100%). With PFGE profiles 282 
BpSR5, BpSR11 and BpSR12, 59 out of 60 isolates carried the Fim3 serotype in the current 283 
study. With fim3 genotype, interestingly all BpSR3 and BpSR10 isolates carried fim3-1 284 
genotype and almost all BpSR5, BpSR11 and BpSR12 isolates carried fim3-2 (60/63, 285 
95.2%). 286 
 287 
Combined analyses of MAST, MLVA and PFGE profiles and their association with 288 
vaccination status of study subjects 289 
The most common profile among the study isolates was ptxP3/prn2/Fim2/MT27/BpSR3 with 290 
50 (18.9%) of 265 isolates. Second was ptxP3/prn2/Fim3/MT27/BpSR10 with 37 (13.9%) 291 
isolates. Third was ptxP3/prn2/Fim3/MT27/BpSR11 with 34 (12.8%) isolates and fourth 292 
ptxP3/prn2/Fim2/MT27/BpSR10 with 20 (7.5%) isolates. 293 
 We compared these main profiles with vaccination status of the subject. We did not 294 
find any significant difference (all p > 0.1) between vaccinated and unvaccinated individuals, 295 
e.g. the  most common profile ptxP3/prn2/Fim2/MT27/BpSR3 was found in isolates from 30 296 
vaccinated and 20 unvaccinated subjects (p = 0.1184).  297 
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 298 
Pertactin deficiency 299 
Of the 265 isolates included in the EUpert IV collection, 66 (24.9%) were found to be PRN 300 
negative, whereas the corresponding frequency was only 6.4% in EUpert III collection (data 301 
not shown). 302 
 303 
DISCUSSION 304 
 305 
In this study we analyzed 265 B. pertussis isolates collected from nine European countries 306 
during the period 2012-2015, and compared the results to three previous EUpert studies 307 
starting in late 1990s. Although the number of participating countries in each study varied, 308 
Finland, France, The Netherlands and Sweden have participated in all four studies. Our study 309 
showed that the dominant alleles ptxA1, ptxP3 and prn2 in circulating strains are different 310 
from those used for production of ACVs in European countries (for Denmark data not 311 
available) (20). However, country based genetic differences of B. pertussis isolates were 312 
identified especially with PFGE analyses. Serotype has also changed from Fim3 to Fim2 in 313 
several countries, although ACVs used in many of these countries do not contain any fimbrial 314 
antigens. 315 
 ACVs contain purified components from strains carrying ptxA2/4, ptxP1 and prn1/7 316 
alleles (excluding Denmark) (20, 21). In this study we found that almost all circulating 317 
isolates harbored different alleles (ptxA1, ptxP3 and prn2) (Table 1). These alleles have been 318 
dominant in the previous EUpert I-III studies, suggesting that circulating B. pertussis with 319 
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16 
these alleles may have advantages in ACV vaccinated populations. This may have an effect 320 
on the vaccine effectiveness (20). Similar findings with the dominant genotypes have been 321 
reported in Australia, Japan and the USA (22-24).  322 
  In Europe many countries use ACVs without the Fim2/Fim3 antigens (Table 323 
1). We found that the frequency of Fim2 isolates has markedly increased in several countries 324 
compared to previous EUpert II and III studies (Figure 1 and Table 2). Both Denmark and 325 
Finland had mostly Fim2 isolates circulating, whereas Fim3 was continuously prevalent in 326 
France, Sweden and the UK (Table 1). In Denmark, a mono-component PT vaccine has been 327 
used for more than 15 years (25). In Finland, ACV was introduced in 2005 and the vaccine 328 
used from 2005 to 2009 contained only PT and FHA. Therefore, the change in frequency 329 
from Fim3 to Fim2 is most likely caused by natural infection. It remains to be shown why a 330 
high frequency of Fim2 isolates is only observed in certain countries. In Japan, where Fim3 331 
allele has been highly dominating since the 21
st
 century (24), two out of four ACVs in use 332 
includes Fim2, which may partly explain why Fim3 is dominant in this country. Similar to 333 
Japan, in France and UK where ACVs containing Fim2/3 are in use (Table 1) and prevalent 334 
serotype of Fim3 was observed. When we compared these findings to previous EUpert III 335 
collection, seven countries were included in both and in Denmark and Finland almost all 336 
isolates were Fim3 in EUpert III collection. In addition, similar, but less dramatic increase of 337 
Fim2 isolates were noticed in Norway and in the UK (although, Fim3 is still prevalent). This 338 
indicates that the numbers are not biased by country changes in different collections, yet they 339 
reflect actual change in the circulating strains.  340 
 In addition to the serotype of the isolates (Fim3), fim3-1 allele became prevalent. 341 
However, in France, Sweden and the UK where Fim3 isolates were prevalent, both genotypes 342 
fim3-1 and fim3-2 were common. It is known that the strains used for production of ACVs 343 
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17 
harbor fim3-1. As stated above, in France and the UK, ACVs containing Fim2/3 are in use, 344 
which could partly explain why strains with fim3-2 were circulating. In addition, natural 345 
infections caused by B. pertussis with different genotypes of fim3-1 and fim3-2 can also have 346 
a selective pressure on circulating isolates. Fim3-1 has also been dominant in the USA during 347 
the recent outbreaks (26). Since expression of Fim2 or Fim3 of B. pertussis might be different  348 
between in vivo and in vitro (13,22), further studies are needed to show whether expression of 349 
Fim3 or Fim2 is related to certain alleles of fim3, fim2 or both. However, according to our 350 
results, it seems that fim3-1 allele is frequently found with Fim2 serotype in Denmark and 351 
Finland. In addition, in the Netherlands during the period 1995-2008, 99% of the fim3-2 352 
strains expressed Fim3 (27). 353 
 We noticed that MT27 is becoming more dominant in Europe, whereas number of 354 
other MTs and SDI, which shows the probability to randomly pick a different isolate from the 355 
whole strain population, (Table 3) clearly decreased compared to previous EUpert I and III 356 
studies. However, this is not the case in Denmark, the only country in these studies where 357 
monocomponent PT vaccine has been used (25). In contrast to other countries, more than 358 
50% of the Danish isolates did not carry MT27. This finding may indicate that effect of 359 
population immunity provided by monocomponent and multicomponent vaccines on bacterial 360 
populations may differ.  In the current study, isolates with MT27 was found equally from 361 
vaccinated (N=106) and unvaccinated (N=108) individuals. However, second most common 362 
profile MT18 was found in 12 unvaccinated and in six vaccinated individuals, whereas third 363 
most common profile MT28 was equal between vaccinated (N=3) and unvaccinated (N=4) 364 
individuals.  365 
   The most common PFGE profiles observed were BpSR3 and BpSR10, 366 
showing an increase in Europe. In contrast, the number of other profiles is decreasing (Figure 367 
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2). Interestingly, the most common profile BpSR3 was not found in Sweden, whereas other 368 
profiles were commonly found among the Swedish isolates, suggesting a shift in the B. 369 
pertussis population in this country. When we compared present findings to earlier results, 370 
PFGE profiles BpSR11 and BpSR10 were dominant in Sweden during the EUpert II and III 371 
collections (7). Pertussis vaccination was stopped in Sweden in 1979 and was reintroduced in 372 
1996 (28). Therefore, the population immunity may be different compared to other countries 373 
in which vaccinations have been continuously used. Similar to Sweden, PFGE profiles 374 
BpSR11 and BpSR10 were common in France and the Netherlands. However, in other 375 
Nordic countries Denmark, Finland and Norway, BpSR3 was the most prevalent PFGE 376 
profile. Denmark and Finland have high similarity within the strains excluding MLVA results 377 
(Table 2). In addition, no outbreaks have been reported in these two countries ten years prior 378 
to 2015 (a country wide epidemic occurred in Denmark in 2016) (29, 30). In the Netherlands, 379 
there has been a shift from BpSR3 to BpSR10, which is currently dominating. This finding is 380 
interesting as similar change was not detected e.g. in France or Sweden. However, in 381 
Belgium, both BpSR3 and BpSR10 were prevalent. This may indicate transmission of the 382 
isolates from neighboring countries or country specific differences in ACVs or in vaccination 383 
policies. In addition, outbreaks prior to 2015 most likely affected on the circulating isolates in 384 
the EUpert IV collection. Association between PFGE profiles and fimbrial serotype revealed 385 
that isolates with BpSR3 and BpSR10 were no longer only associated with Fim3, but were 386 
moving towards Fim2 serotype. We also compared vaccination status and three most 387 
common PFGE profiles, BpSR10, BpSR3 and BpSR11. These profiles were found almost 388 
equally among vaccinated and unvaccinated individuals. Still, we noticed that the number of 389 
profiles were decreasing and BpSR3 and BpSR10 were clearly dominant. In addition, the SDI 390 
was decreasing for PFGE (Table 3), which also indicates that the strains are more similar than 391 
previously. 392 
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 Although, we did not find any significant differences in the B. pertussis strains 393 
isolated from vaccinated and unvaccinated individuals, it does not signify that vaccination 394 
has not guided the strains to evolve more homogenously. However, it seems that PFGE and 395 
serotyping have the most discriminating power in this study, whereas MLVA is losing its 396 
power as shown by the SDI. Therefore the use of whole genome sequencing (WGS), should 397 
be considered to have more insight on the strains. Indeed, one WGS study from the UK 398 
showed that mutations in the ACV antigen genes have significantly increased after the 399 
introduction of ACVs, but variations in other surface antigen genes are minor (2). Another 400 
recent WGS study from Australia have identified five single nucleotide polymorphisms 401 
which were common in the epidemic isolates and differentiated them from pre-epidemic 402 
isolates, stressing the role of WGS in studying of B. pertussis (23). However, little is still 403 
known about the impact of all mutations in the B. pertussis genome. 404 
 The number of PRN deficient isolates is alarming. In this study we found that 405 
approximately 25% of the study strains did not produce this antigen. How this will affect to 406 
vaccine efficacy and to opinions towards pertussis vaccination remains to be seen. A detailed 407 
description of PRN deficient isolates and the mechanisms behind the deficiency observed in 408 
this study is currently under consideration for publication elsewhere. 409 
 The strengths of this study are, 1) We have a serial collection of isolates during the 410 
last 15 years, 2) Selection criteria has been the same for all collections, 3) isolates have been 411 
isolated from infants, young children and adults (range: 0·01 – 62·30 years), 4) the place of 412 
origin is known for all isolates and shows that they were not collected from local outbreaks 413 
and 5) all analyses for the EUpert IV panel strains were done by one laboratory. The 414 
limitations included 1) the number of isolates from each country was relatively low (range: 415 
20-38). However, they do comprise almost all available isolates in many countries such as 416 
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Denmark, Finland and Italy, where the use of culture is diminishing, 2) The epidemiological 417 
pressure of pertussis varies in European countries, which could have an effect on the spread 418 
of new emerging strains, and 3) Even though the total number of vaccinated and 419 
unvaccinated individuals included in this study was comparable (Table 2), the difference in 420 
numbers between  vaccinated and unvaccinated subjects in individual countries existed. To 421 
avoid such effect, a study with a large number of isolates and equal number of those from 422 
vaccinated and unvaccinated individuals in participating countries is needed. 423 
 In conclusion, common MLVA types and PFGE profiles were identified in B. 424 
pertussis populations circulating in European countries with different vaccination programs. 425 
The prevalent MT types and PFGE profiles contain the ptxA1/prn2/ptxP3 alleles. However, in 426 
contrast to the high prevalence (78.9-90.6%) of MT27 in most European countries using two 427 
and three components ACVs, the prevalence in Denmark (PT monocomponent ACV) 428 
represented only 48.1% of the circulating strains, suggesting a difference in selection pressure 429 
induced between these ACVs. In addition, the shift in serotype from Fim3 and Fim2 is 430 
ongoing in several countries. This study suggests that the B. pertussis population is moving 431 
towards homogeneity in European countries. To get more deep insight of the B. pertussis 432 
strain diversity in Europe, whole genome sequencing could be applied for surveillance of B. 433 
pertussis.  434 
 435 
 436 
 437 
 438 
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TABLES AND FIGURES 571 
Table 1. Pertussis vaccines currently used in European countries* 572 
 573 
Country      Vaccine 574 
Belgium      ACV3 575 
Denmark      ACV1 576 
Finland      ACV3 577 
France       ACV2, ACV3 or ACV5 578 
Italy       ACV3 579 
Norway      ACV3 580 
Sweden      ACV2 or ACV3 581 
The Netherlands     ACV3 582 
UK       ACV3 or ACV5 583 
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*Vaccine compositions: ACV1: PT; ACV2: PT and FHA; ACV3: PT, FHA and PRN; ACV5: 584 
PT, FHA, PRN, Fim2 and Fim3 585 
 586 
 587 
 588 
 589 
 590 
 591 
 592 
 593 
 594 
 595 
  596 
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Table 2. Overview of the isolate characteristics in EUpert IV study countries 597 
 598 
 
COUNTRY 
 
 
Belgium Denmark Finland France Italy Netherlands Norway Sweden UK TOTAL 
No. of Strains 38 27 28 29 20 32 32 29 30 265 
          
  
vaccination status 
         
  
vaccinated 14 11 16 15 2 24 24 11 13 130 
unvaccinated/unknown 24 16 12 14 18 8 8 18 17 135 
          
  
ptxA genotype 
         
  
ptxA1 38 27 28 29 20 32 32 29 30 265 
          
  
ptxP genotype 
         
  
ptxP1 1 1 2 3 1 0 1 2 1 12 
ptxP3 37 26 26 26 19 32 31 27 29 253 
          
  
Serotype 
         
  
Fim2 17 22 22 2 10 15 16 5 11 120 
Fim3 21 5 6 27 9 15 15 24 19 141 
Fim2,3 0 0 0 0 1 2 0 0 0 3 
Negative 0 0 0 0 0 0 1 0 0 1 
          
  
fim3-allele 
         
  
 fim3-1 30 24 22 14 15 24 27 17 17 190 
fim3-2 8 3 3 15 5 8 5 12 13 72 
fim3-3 0 0 1 0 0 0 0 0 0 1 
fim3-4 (1b) 0 0 2 0 0 0 0 0 0 2 
          
  
prn genotype 
         
  
prn1 1 0 2 0 0 0 0 0 0 3 
prn2 35 26 25 27 20 32 31 29 30 255 
prn3 0 0 1 1 0 0 0 0 0 2 
prn9 2 1 0 1 0 0 1 0 0 5 
          
  
PFGE profile 
         
  
BpSR3 12 18 16 3 6 2 14 0 7 78 
BpSR5 2 0 1 2 0 2 0 3 4 14 
BpSR10 16 2 2 7 3 16 8 11 7 72 
BpSR11 3 2 2 9 2 7 3 7 4 39 
BpSR12 2 1 0 2 1 0 1 1 2 10 
Others 3 4 7 6 8 5 6 7 6 52 
          
  
MLVA type 
         
  
MT27 30 13 24 23 18 29 26 24 27 214 
Others 8 14 4 6 2 3 6 5 3 51 
 599 
 600 
 601 
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Table 3. Number of PFGE profiles and MLVA types dentified in the four study periods 602 
 603 
  Percentage (%) of PFGE or MLVA types (identified/total no of isolates)          604 
                        ______________________________________________________________________ 605 
Method   1998-2001 2004-2005 2007-2009 2012-2015 606 
PFGE    32.4 (33/102) 23.4 (36/154)     18.8 (29/140)  15.8 (42/265)  607 
MLVA   17.6 (18/102)         N/A†             10.7 (15/140)      7.5 (20/265) 608 
 609 
*The Simpson diversity index calculated for each study period was 0.91, 0.88, 0.88 and 0.83 610 
for PFGE and 0.70, 0.47 and 0.34 for MLVA.  611 
†*N/A, not available. 612 
 613 
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Figure legends 633 
Figure 1. Frequency of fimbrial serotypes among the EUpert I-IV studies 634 
Figure 2. Distribution of PFGE profiles among the EUpert I-IV studies (1998-2015) 635 
Figure 3. Distribution of PFGE profiles among the EUpert IV study countries (2012-2015) 636 
Figure 4. Dendogram of PFGE profiles identified in the EUpert IV study 637 
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Figure 1. 663 
 664 
 665 
 666 
 667 
 668 
 669 
 670 
 671 
 672 
 673 
 674 
 675 
 676 
 677 
 678 
 679 
 680 
 681 
 o
n
 April 3, 2018 by SYDDANSK UNIVERSITETSBIBLIO
TEK
http://jcm.asm.org/
D
ow
nloaded from
 
 
33 
Figure 2. 682 
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Figure 3.  702 
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Figure 4. 721 
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